BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20007543)

  • 1. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
    Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
    Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
    Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
    Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
    Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.
    Efimenko E; Davé UP; Lebedeva IV; Shen Y; Sanchez-Quintero MJ; Diolaiti D; Kung A; Lannutti BJ; Chen J; Realubit R; Niatsetskaya Z; Ten V; Karan C; Chen X; Califano A; Diacovo TG
    Mol Cancer Ther; 2017 Oct; 16(10):2069-2082. PubMed ID: 28716817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances on NOTCH signaling in T-ALL.
    Tzoneva G; Ferrando AA
    Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
    Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
    Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to γ-secretase inhibition.
    Hounjet J; Habets R; Schaaf MB; Hendrickx TC; Barbeau LMO; Yahyanejad S; Rouschop KM; Groot AJ; Vooijs M
    Oncogene; 2019 Jul; 38(27):5457-5468. PubMed ID: 30967635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antileukemic therapies in
    Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
    Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
    Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
    Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
    J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
    Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
    Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
    Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA
    Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
    Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
    Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
    López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
    Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.